B

광동제약

009290KOSPI

55.4 / 100

Reference Date: 2026-09-08

Financial Score24.0 / 40
News Sentiment17.4 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Slightly down 2.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Guangdong Pharmaceutical operates through three divisions—OTC, ETC, and F&B—selling products like Cheongshimwon, Jeju Samdaewon, and Gardasil, with 98.6% of sales coming from the domestic market. In 2025, the company achieved sales of 10.11 trillion KRW and aims to expand into natural product markets, digital innovation, and healthcare platforms to become a 'Human Healthcare Brand' enterprise.

Number of Employees

1,022people

Average Salary

78.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
12.05Industry Average 15.005.0Point

In line with industry avg

PBR
0.44Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE
3.21Industry Average 8.001.0Point

Well below industry avg

Debt Ratio
11.61Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲4.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼12.7% (2-year basis)

ROE Trend
2.0 / 4

Avg ROE 5.7% (declining, 3yr)

Detailed News Sentiment

15 totalPositive 9Neutral 2Negative 4Average Sentiment Score 69.7

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 6,280Won52-week high 11,08052-week low 5,270
1-month return2.0Point

1m -2.79% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral최대주주등소유주식변동신고서2026-08-28
  • Neutral반기보고서 (2026.06)2026-08-14
  • Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-08-12